These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20861258)

  • 1. BST-2 diminishes HIV-1 infectivity.
    Zhang J; Liang C
    J Virol; 2010 Dec; 84(23):12336-43. PubMed ID: 20861258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles.
    Fitzpatrick K; Skasko M; Deerinck TJ; Crum J; Ellisman MH; Guatelli J
    PLoS Pathog; 2010 Mar; 6(3):e1000701. PubMed ID: 20221443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.
    Sharma S; Jafari M; Bangar A; William K; Guatelli J; Lewinski MK
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-Dimensional Structural Characterization of HIV-1 Tethered to Human Cells.
    Strauss JD; Hammonds JE; Yi H; Ding L; Spearman P; Wright ER
    J Virol; 2016 Feb; 90(3):1507-21. PubMed ID: 26582000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetherin restricts productive HIV-1 cell-to-cell transmission.
    Casartelli N; Sourisseau M; Feldmann J; Guivel-Benhassine F; Mallet A; Marcelin AG; Guatelli J; Schwartz O
    PLoS Pathog; 2010 Jun; 6(6):e1000955. PubMed ID: 20585562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BST-2 restricts IAV release and is countered by the viral M2 protein.
    Hu S; Yin L; Mei S; Li J; Xu F; Sun H; Liu X; Cen S; Liang C; Li A; Guo F
    Biochem J; 2017 Feb; 474(5):715-730. PubMed ID: 28087685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
    Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
    J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inhibition of HIV virus-like particles production by BST-2].
    Du YL; Hu SQ; Pang XJ; Cen S; Jin Q; Guo F
    Bing Du Xue Bao; 2011 Jul; 27(4):319-25. PubMed ID: 21874899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
    Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
    Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The great escape: viral strategies to counter BST-2/tetherin.
    Douglas JL; Gustin JK; Viswanathan K; Mansouri M; Moses AV; Früh K
    PLoS Pathog; 2010 May; 6(5):e1000913. PubMed ID: 20485522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative multicolor super-resolution microscopy reveals tetherin HIV-1 interaction.
    Lehmann M; Rocha S; Mangeat B; Blanchet F; Uji-I H; Hofkens J; Piguet V
    PLoS Pathog; 2011 Dec; 7(12):e1002456. PubMed ID: 22194693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.
    Van Damme N; Goff D; Katsura C; Jorgenson RL; Mitchell R; Johnson MC; Stephens EB; Guatelli J
    Cell Host Microbe; 2008 Apr; 3(4):245-52. PubMed ID: 18342597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells.
    Jolly C; Booth NJ; Neil SJ
    J Virol; 2010 Dec; 84(23):12185-99. PubMed ID: 20861257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetherin restricts direct cell-to-cell infection of HIV-1.
    Kuhl BD; Sloan RD; Donahue DA; Bar-Magen T; Liang C; Wainberg MA
    Retrovirology; 2010 Dec; 7():115. PubMed ID: 21184674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-throughput assay to identify inhibitors of Vpu-mediated down-regulation of cell surface BST-2.
    Zhang Q; Liu Z; Mi Z; Li X; Jia P; Zhou J; Yin X; You X; Yu L; Guo F; Ma J; Liang C; Cen S
    Antiviral Res; 2011 Sep; 91(3):321-9. PubMed ID: 21777622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation.
    Janvier K; Pelchen-Matthews A; Renaud JB; Caillet M; Marsh M; Berlioz-Torrent C
    PLoS Pathog; 2011 Feb; 7(2):e1001265. PubMed ID: 21304933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The size and conservation of a coiled-coil structure in the ectodomain of human BST-2/tetherin is dispensable for inhibition of HIV-1 virion release.
    Andrew AJ; Berndsen CE; Kao S; Strebel K
    J Biol Chem; 2012 Dec; 287(53):44278-88. PubMed ID: 23152502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.
    Iwabu Y; Fujita H; Kinomoto M; Kaneko K; Ishizaka Y; Tanaka Y; Sata T; Tokunaga K
    J Biol Chem; 2009 Dec; 284(50):35060-72. PubMed ID: 19837671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe Acute Respiratory Syndrome Coronavirus ORF7a Inhibits Bone Marrow Stromal Antigen 2 Virion Tethering through a Novel Mechanism of Glycosylation Interference.
    Taylor JK; Coleman CM; Postel S; Sisk JM; Bernbaum JG; Venkataraman T; Sundberg EJ; Frieman MB
    J Virol; 2015 Dec; 89(23):11820-33. PubMed ID: 26378163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion.
    Miyagi E; Andrew AJ; Kao S; Strebel K
    Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2868-73. PubMed ID: 19196977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.